Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Castle Biosciences Total Payout Ratio Related Terms
Castle Biosciences Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs FLGT, MYGN, OPK: Total Payout Ratio Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Total Payout Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a Total Payout Ratio of 0.00 as of Jul. 23, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Total Payout Ratio too high?
Castle Biosciences' current Total Payout Ratio is 0.00. Overall, Castle Biosciences has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Total Payout Ratio compare to FLGT and MYGN?
Castle Biosciences' Total Payout Ratio of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Diagnostics & Research company?
A good Total Payout Ratio depends on the Medical Diagnostics & Research industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.21, compared to a current price of $24.85 — trading 14.9% below its estimated fair value. The current Total Payout Ratio is 0.00. Castle Biosciences' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Total Payout Ratio is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $24.85 is trading 14.9% below its estimated GF Value™ of $29.21.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Total Payout Ratio: 0.00
GF Value™: $29.21 vs. price of $24.85 (14.9% below fair value)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
79GF Score
Get the complete analysis for CSTL
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
